



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

## Rosuvastatin calcium

October 16, 2018

### **Non-proprietary name**

Rosuvastatin calcium

### **Safety measure**

Precautions should be revised in the package insert.

The following language should be deleted from the Relative Contraindications section:

This drug should be co-administered with fibrates in patients with abnormal renal function values only when such use is deemed to be absolutely necessary for treatment.

The following language should be added to the Important Precautions section (revised language is underlined):

This drug should be co-administered with fibrates in patients with abnormal renal function values only when such use is deemed to be absolutely necessary for treatment.

Rhabdomyolysis accompanied by rapid deterioration of renal function tends to occur. When administration of this drug in combination with fibrates is unavoidable, clinical laboratory tests examining renal function should be performed periodically. If appearance of subjective symptoms (myalgia, feeling of weakness), increased CK (CPK) level, increased blood or urine myoglobin level, or signs of diminished renal function such as increased serum creatinine level is observed, administration of this drug combination should be discontinued immediately.

Published by  
Ministry of Health, Labour and Welfare



Translated by  
Pharmaceuticals and Medical Devices Agency



---

*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

The following language should be deleted from the Relative Contraindications for Co-administration subsection of the Interactions section:

Fibrates (e.g., bezafibrate (in patients with abnormal renal function values))

**Pharmaceuticals and Medical Devices Agency**

Office of Safety I

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan

E-mail: [safety.info@pmda.go.jp](mailto:safety.info@pmda.go.jp)